Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Neoadjuvant Therapy Neoplasm Staging Estrogen Receptor Histological Grade HER2 Prognosis Predictive Value of Tests A patient will be eligible for in this study if he or she meets all of the following 1. Has operable, histologically confirmed, Stage I, IIA, IIB, IIIA, IIIB or IIIC invasive carcinoma of the breast. 2. Has had neoadjuvant chemotherapy before operation for this breast cancer. 3. Age >=18 to <=75 years old. 4. Has known ER and PR status. 5. Has known HER-2 status. 6. Has known menopausal status. 7. Before PST, Lymph nodes were evaluated by fine needle biopsy (FNB) if the clinically positive, or by sentinel lymph nodes biopsy (SLNB) if the clinically or FNB negative. 8. Has complete surgical resection of the primary breast tumor after PST: either lumpectomy or mastectomy with sentinel lymph node biopsy or axillary dissection, with clear margins for both invasive and ductal carcinoma in situ (DCIS). 9. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. 10. Has laboratory values of White blood cell count >3000/mm3 Absolute neutrophil count (ANC) ≥1500/mm3 Hemoglobin ≥9.0 g/dL Total bilirubin <ULN Serum creatinine ≤1.5 mg/dL Platelet count ≥100,000/mm3 ULN = upper limit of normal 11. Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within any of the ranges shown below ALP ≤ upper limits of normal(ULN),and AST or ALT ≤ 5 ULN ULN < ALP ≤2.5 ULN, and AST or ALT ≤ 1.5 ULN  A patient will be excluded from this study if she meets any of the following 1. Has bilateral synchronous breast cancer. 2. Has any evidence of metastatic disease: staging work-up, biopsy or physical examination suspicious for malignant disease. 3. Has a history of severe hypersensitivity reaction to chemotherapy drugs or formulation. 4. Has a history of heart failure, uncontrolled angina, severe uncontrolled arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic changes. 5. Has peripheral neuropathy >Grade 1. 6. Has had a major organ allograft or condition requiring chronic immunosuppression (ie, kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases). Patients who have received corneal transplants or cadaver skin or bone transplants are eligible. 7. Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral [including clinically defined acquired immune deficiency syndrome (AIDS)], bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or central nervous system (CNS) disorders deemed by the Treating Physician to be clinically significant, precluding informed consent. 8. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be human immunodeficiency virus (HIV) positive. 9. Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin, carcinoma in situ of uterine cervix, DCIS), which could affect the diagnosis or assessment of any of the study drugs. 10. Is deemed unable to comply with requirements of study